HomeCompareVINE vs ABBV

VINE vs ABBV: Dividend Comparison 2026

VINE yields 347.83% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VINE wins by $4191.61M in total portfolio value
10 years
VINE
VINE
● Live price
347.83%
Share price
$0.58
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4191.71M
Annual income
$2,677,457,066.40
Full VINE calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VINE vs ABBV

📍 VINE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVINEABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VINE + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VINE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VINE
Annual income on $10K today (after 15% tax)
$29,565.22/yr
After 10yr DRIP, annual income (after tax)
$2,275,838,506.44/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, VINE beats the other by $2,275,817,450.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VINE + ABBV for your $10,000?

VINE: 50%ABBV: 50%
100% ABBV50/50100% VINE
Portfolio after 10yr
$2095.91M
Annual income
$1,338,740,919.08/yr
Blended yield
63.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VINE
No analyst data
Altman Z
-1.0
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VINE buys
0
ABBV buys
0
No recent congressional trades found for VINE or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVINEABBV
Forward yield347.83%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4191.71M$102.3K
Annual income after 10y$2,677,457,066.40$24,771.77
Total dividends collected$4046.69M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VINE vs ABBV ($10,000, DRIP)

YearVINE PortfolioVINE Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$45,483$34,782.61$11,550$430.00+$33.9KVINE
2$196,517$147,850.82$13,472$627.96+$183.0KVINE
3$807,302$597,028.67$15,906$926.08+$791.4KVINE
4$3,155,984$2,292,170.37$19,071$1,382.55+$3.14MVINE
5$11,751,458$8,374,555.78$23,302$2,095.81+$11.73MVINE
6$41,717,112$29,143,051.52$29,150$3,237.93+$41.69MVINE
7$141,325,564$96,688,254.17$37,536$5,121.41+$141.29MVINE
8$457,341,687$306,123,333.58$50,079$8,338.38+$457.29MVINE
9$1,415,188,738$925,833,132.77$69,753$14,065.80+$1415.12MVINE
10$4,191,709,016$2,677,457,066.40$102,337$24,771.77+$4191.61MVINE

VINE vs ABBV: Complete Analysis 2026

VINEStock

Fresh Vine Wine, Inc. produces and sells low-carb and low-calorie wines in the United States and Puerto Rico. Its wine varietals include cabernet sauvignon, pinot noir, chardonnay, and rose. The company offers its products through wholesale, retail, and direct-to-consumer channels. Fresh Vine Wine, Inc. was founded in 2019 and is based in Plymouth, Minnesota.

Full VINE Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VINE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VINE vs SCHDVINE vs JEPIVINE vs OVINE vs KOVINE vs MAINVINE vs JNJVINE vs MRKVINE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.